Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 17/20 | 0.79 |
| ▸ | CHRNA4 | P43681 | 17/20 | 0.79 |
| ▸ | CHRNB4 | P30926 | 15/20 | 0.79 |
| ▸ | CHRNA3 | P32297 | 15/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL650701 | 1.00 | CHRNB2 (0.79) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Fumaric Acid SCHEMBL650704 | 1.00 | CHRNB2 (0.79) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Fumaric Acid SCHEMBL650703 | 1.00 | CHRNB2 (0.79) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Fumaric Acid SCHEMBL651856 | 1.00 | CHRNB2 (0.79) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Fumaric Acid SCHEMBL652426 | 0.90 | CHRNB2 (0.80) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Fumaric Acid SCHEMBL649420 | 0.90 | CHRNB2 (0.80) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Fumaric Acid SCHEMBL649422 | 0.90 | CHRNB2 (0.80) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Fumaric Acid SCHEMBL654629 | 0.90 | CHRNB2 (0.80) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL650184 | 0.89 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL650247 | 0.89 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037614-B2 | Lipase variants and microcapsule compositions comprising such lipase variants | NOVOZYMES A/S (DK) | 2024-07-16 | — | — | US | disclosed |
| WO-2024121058-A1 | A COMPOSITION COMPRISING A LIPASE AND A PEPTIDE | NOVOZYMES A/S (DK) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024121057-A1 | A COMPOSITION FOR REMOVING BODY GRIME | NOVOZYMES A/S (DK) | 2024-06-13 | — | — | WO | disclosed |
| EP-4357453-A2 | LIPASE VARIANTS, POLYNUCLEOTIDES ENCODING SAME AND THE USE THEREOF | Novozymes A/S (DK) | 2024-04-24 | — | — | EP | disclosed |
| US-20240060060-A1 | METHODS OF REDUCING ODOR | NOVOZYMES A/S (DK) | 2024-02-22 | — | — | US | disclosed |
| US-20240035005-A1 | LIPASE VARIANTS AND COMPOSITIONS COMPRISING SUCH LIPASE VARIANTS | NOVOZYMES A/S (DK) | 2024-02-01 | — | — | US | disclosed |
| EP-3485008-B1 | LIPASE VARIANTS, POLYNUCLEOTIDES ENCODING SAME AND THE USE THEREOF | NOVOZYMES AS (DK) | 2024-01-31 | — | — | EP | disclosed |
| WO-2023247664-A2 | LIPASE VARIANTS AND COMPOSITIONS COMPRISING SUCH LIPASE VARIANTS | NOVOZYMES A/S (DK) | 2023-12-28 | — | — | WO | disclosed |
| US-20230407209-A1 | Detergent Composition Comprising a Lipase | NOVOZYMES A/S (DK) | 2023-12-21 | — | — | US | disclosed |
| US-20230365948-A1 | Lipase Variants and Polynucleotides Encoding Same | NOVOZYMES A/S (DK) | 2023-11-16 | — | — | US | disclosed |
| EP-1811014-A1 | A composition comprising a pre-formed peroxyacid and a bleach catalyst | The Procter and Gamble Company (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20070123441-A1 | Stable odorant systems | PROCTER & GAMBLE COMPANY, THE | 2007-05-31 | — | — | US | disclosed |
| US-20070123440-A1 | Stable odorant systems | THE PROCTER & GAMBLE COMPANY | 2007-05-31 | — | — | US | disclosed |
| WO-2007060645-A2 | STABLE ODORANT SYSTEMS | THE PROCTER & GAMBLE COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| EP-1704217-A1 | ORGANIC CATALYST SYSTEM | The Procter and Gamble Company (US) | 2006-09-27 | — | — | EP | disclosed |
| WO-2005073360-A1 | ORGANIC CATALYST SYSTEM | THE PROCTER & GAMBLE COMPANY (US) | 2005-08-11 | — | — | WO | disclosed |
| US-20050159327-A1 | Organic catalyst system | THE PROCTER & GAMBLE COMPANY | 2005-07-21 | — | — | US | disclosed |
| US-6809105-B2 | (CIS)-6-(3-PYRIDINYL)-3,6-DIAZABICYCLO(3.2.0) HEPTANE FOR EXAMPLE; ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, ATTENTION DEFICIT HYPERACTIVITY DISORDER, DEPRESSION, NICOTINIC WITHDRAWAL SYNDROME, TOURETTE'S SYNDROME, AND SCHIZOPHRENIA | ABBOTT LABORATORIES | 2004-10-26 | — | — | US | disclosed |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2004-09-23 | — | — | US | disclosed |
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | ABBVIE INC. | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019388-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | CHRNB2 11/4885CHRNA4 8/4885CHRNB4 15/4885 |
| US-20040186107-A1 | Diazabicyclic central nervous system active agents | GAP43, GABRE, CHRNA6 | CHRNB2 11/4885CHRNA4 8/4885CHRNB4 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.